Research programme: NSAC compounds - Helsinn Therapeutics

Drug Profile

Research programme: NSAC compounds - Helsinn Therapeutics

Alternative Names: NSAC

Latest Information Update: 07 May 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics
  • Class Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase Unknown Unspecified
  • No development reported Bone resorption; Fracture; Metabolic disorders; Muscular atrophy

Most Recent Events

  • 18 May 2006 No development reported - Preclinical for Bone resorption in USA (unspecified route)
  • 18 May 2006 No development reported - Preclinical for Fracture in USA (unspecified route)
  • 18 May 2006 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top